Compare · BDX vs NYXH
BDX vs NYXH
Side-by-side comparison of Becton Dickinson and Company (BDX) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.32B, about 332.9x NYXH ($130.1M).
- Over the past year, BDX is down 25.7% and NYXH is down 49.8% - BDX leads by 24.1 points.
- BDX has hit the wire 9 times in the past 4 weeks while NYXH has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 8 for NYXH).
- Company
- Becton Dickinson and Company
- Nyxoah SA
- Price
- $152.11-1.77%
- $2.98-2.93%
- Market cap
- $43.32B
- $130.1M
- 1M return
- -3.89%
- -5.85%
- 1Y return
- -25.68%
- -49.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 8
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest BDX
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD
- For Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
- BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
- When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
- SEC Form 4 filed by Neal Shana Carol
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NYXH
- SEC Form S-8 filed by Nyxoah SA
- SEC Form 20-F filed by Nyxoah SA
- Publication relating to transparency notifications
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Publication relating to transparency notification
- Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
- Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
- Publication relating to transparency notifications
- Information on the total number of voting rights and shares